News | December 07, 2012

SFA Stents Show Acceptable Long Term Patency

December 7, 2012 — More than half of patients treated for claudication or critical limb ischemia (CLI) with stenting of the superficial femoral artery (SFA) had primary patency at five years.

“Stenting of the SFA is associated with an acceptable success rate even after five years and in patients with long SFA lesions,” noted Giovanni Torsello, M.D., at the 39th annual VEITHsymposium.

Primary patency rates for 517 patients were, respectively, 86 percent, 75 percent and 61 percent at one, three and five years. Primary patency was defined as the absence of hemodynamically-significant stenosis on duplex ultrasound imaging (systolic velocity ratio <2.4) at the target lesion and without target lesion revascularization (TLR). There were no significant difference between TASC A/B and TASC C/D lesions groups or between bare-metal stents and drug-eluting, said Torsello, who is the chief of the department of vascular surgery at St. Franziskus-Hospital in Münster, Germany.

The results come from a retrospective review of 517 patients who reached a follow-up of at least 2 years. Overall 827 stents were implanted in 543 limbs.

More than three quarters of patients (77.9 percent) were treated for claudication, and the remaining patients were treated for CLI. TASC II C or D lesions were seen in 35.5 percent of patients, based on angiography. Complete occlusion in was seen in 42.7 percent and 13.8 percent had popliteal involvement. The average lesion length was 154.2 ±94.0 mm. After a mean follow-up of 93.4 ±1.6 months, 18.8 percent of patients died.  Mean ankle-brachial index increased from 0.67 ±0.17 to 0.98±1.7 at follow up (p<0.001). TLR was performed in 27.8 percent of the limbs treated. In addition, secondary patency rates were 95 percent, 90 percent and 76 percent after one, three and five years. Eight patients (1.5 percent) underwent major amputation.

For more information:

Related Content

Lexington Begins HeartSentry Clinical Trial
News | Clinical Study | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Clinical Study | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Clinical Study | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init